CRISPR

CRISPR1-gp9

ID
ZDB-CRISPR-221010-2
Name
CRISPR1-gp9
Previous Names
None
Target
Sequence
5' - GGGCAAAGTCACGCACCTGC - 3'
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
None
Genome Resources
None
Target Location
Genome Build: GRCz11Chromosome: 23
Constructs
No data available
Genomic Features
Genomic Feature Affected Genomic Regions
sm17 gp9
Expression
Gene expression in Wild Types + CRISPR1-gp9
No data available
Phenotype
Phenotype resulting from CRISPR1-gp9
No data available
Phenotype of all Fish created by or utilizing CRISPR1-gp9
Phenotype Fish Conditions Figures
caudal hematopoietic tissue cell population proliferation decreased process quality, abnormal gp9sm17/sm17; la2Tg standard conditions Fig. 5 from Lin et al., 2021
thromboblast cell population proliferation decreased process quality, abnormal gp9sm17/sm17; la2Tg standard conditions Fig. 5 from Lin et al., 2021
whole organism zfpm1 expression decreased amount, abnormal gp9sm17/sm17; la2Tg standard conditions Fig. 4 from Lin et al., 2021
blood thromboblast increased amount, abnormal gp9sm17/sm17; la2Tg standard conditions Fig. 4 from Lin et al., 2021
head kidney thromboblast increased amount, abnormal gp9sm17/sm17; la2Tg standard conditions Fig. 2 from Lin et al., 2021
caudal fin blood coagulation decreased process quality, abnormal gp9sm17/sm17; la2Tg transection: caudal fin Fig. 3 from Lin et al., 2021
caudal hematopoietic tissue thrombocyte amount, ameliorated gp9sm17/sm17; la2Tg chemical treatment by environment: 5-aza-2'-deoxycytidine Fig. 7 from Lin et al., 2021
head kidney hematopoietic stem cell increased amount, abnormal gp9sm17/sm17; la2Tg standard conditions Fig. 2 from Lin et al., 2021
whole organism itga2b expression decreased amount, abnormal gp9sm17/sm17; la2Tg standard conditions Fig. 4 from Lin et al., 2021
caudal fin accumulation blood, abnormal gp9sm17/sm17; la2Tg standard conditions Fig. 3 from Lin et al., 2021
caudal hematopoietic tissue blood coagulation decreased process quality, abnormal gp9sm17/sm17; la2Tg chemical treatment by environment: iron trichloride Fig. 3 from Lin et al., 2021
blood thrombocyte decreased amount, abnormal gp9sm17/sm17; la2Tg standard conditions Fig. 2Fig. 4 from Lin et al., 2021
head kidney hematopoietic multipotent progenitor cell increased amount, abnormal gp9sm17/sm17; la2Tg standard conditions Fig. 2 from Lin et al., 2021
gill blood coagulation decreased process quality, abnormal gp9sm17/sm17; la2Tg chemical treatment by environment: sodium hydroxide Fig. 3 from Lin et al., 2021
caudal hematopoietic tissue thrombocyte amount, ameliorated gp9sm17/sm17; la2Tg chemical treatment by environment: thrombopoietin receptor agonist Fig. 7 from Lin et al., 2021
whole organism nfe2 expression decreased amount, abnormal gp9sm17/sm17; la2Tg standard conditions Fig. 4 from Lin et al., 2021
caudal hematopoietic tissue thrombocyte decreased amount, abnormal gp9sm17/sm17; la2Tg control Fig. 4Fig. 6Fig. 7 from Lin et al., 2021
Citations